Faza badania

Otwarte badanie 2 fazy

Czas trwania badania

Screening will take place within 21 days of the first treatment visit. Treatment visits will occur over 4 cycles and an End-of-Treatment Visit after completion of the last 21-dav cvcle of study treatment.

Follow-up Visits for disease progression will be conducted by radiologie assessments every 6 weeks (± 7 days) until one of the following occurs: disease progression, patient initiates non-study cancer treatment, patient withdraws consent, or becomes lost-to-follow-up.

Survival data will be captured by telephone call every 30 days (± 7 days) and patients will be followed until deat.

Wskazanie

Immunokoniugat L-DOS47 w połączeniu z winorelbiną / cisplatyną w porównaniu z samą winorelbiną / cisplatyną u pacjentów z przerzutowym gruczolakorakiem płuc

• Nowotwór złośliwy oskrzela i płuca – C34  Aktywne